The SODIUM-HF trial tested whether or not a reduction in dietary sodium reduces the incidence of heart failure. touchCARDIO speaks with Prof. Justin Ezekowitz (University of Alberta, Edmonton, Canada) to discuss his presentation on the SODIUM-HF study on the effect of sodium restriction on mortality and morbidity in patients with heart failure.
The presentation entitled ‘SODIUM-HF: Study of Dietary Intervention Under 100 Mmol in Heart Failure’ was presented at the American College of Cardiology Annual Meeting 2022, April 02-04, 2022
Questions:
- What is currently known about the effect of sodium restriction on mortality and morbidity in patients with heart failure? (00:23)
- What were the aims and design of the SODIUM-HF study? (01:04)
- What were the primary and secondary endpoints, and how well were they achieved? (02:18)
- Which patients were most likely to benefit from this intervention? (04:25)
- On the basis of these findings, what are your recommendations for clinical practice, and what further research is needed? (05:57)
Disclosures: Justin Ezekowitz is a consultant for American Regent, Amgen, AstraZeneca, Bayer, Bristol-Meyers Squibb, Merck, Sanofi and Servier and received grants/research support from American Regent, Amgen, AstraZeneca, Bayer, Bristol-Meyers Squibb, Merck, Sanofi, Servier, Ortho-Biotech/Johnson & Johnson and Eko
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Shanice Allen.
Filmed in coverage of the American College of Cardiology Annual Meeting 2022
